Philip Storey
PHILADELPHIA — Mounting evidence from an ongoing multicenter collaboration demonstrates that anti-VEGF injection via prefilled syringe may substantially reduce the risk of endophthalmitis compared with the conventional method of injection, Philip Storey, MD, MPH, said at the Wills Eye Conference.
Storey and colleagues conducted a retrospective case-control study of all patients with endophthalmitis at Wills Eye Hospital following a conventional vs. prefilled syringe method of delivering Lucentis (ranibizumab, Genentech) over a 2-year period. The incidence of endophthalmitis
Uncategorized